QL1A Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Ex-China Revenue ResilienceGrowth across major franchises outside China demonstrates resilient underlying demand and reduces dependence on any single geography. Expansion in laboratories, immunohematology, and point-of-care testing can support a broader installed base and recurring consumables revenue over the coming quarters.
EBITDA And Margin ExpansionMeaningful EBITDA growth and margin expansion indicate that operating leverage and cost control are strengthening earnings capacity despite a seasonally weak quarter. If maintained, the improved margin profile can support reinvestment, debt reduction, and more durable cash conversion.
New Product Platform ExpansionThe Lex and Neulixa commercialization effort broadens QuidelOrtho’s respiratory offering and provides an additional platform for instrument placements and recurring test utilization. Progress toward manufacturing readiness, customer adoption, and future seasonal launches could strengthen the company’s product portfolio.
Bears Say
Persistent Profitability And Cash BurnDeep operating losses and negative recent cash generation show that the business is not currently funding itself through operations. Continued cash consumption can constrain investment, increase reliance on financing, and delay the point at which revenue growth translates into durable shareholder returns.
Elevated Leverage And Covenant PressureLeverage of 4.3x adjusted EBITDA leaves debt reduction and cash conversion as important priorities. The amended credit agreement also includes staged covenant levels, pricing changes, and restrictions, which may reduce financial flexibility while operating performance remains under pressure.
China Pricing-policy UncertaintyRegulatory pricing uncertainty in China is affecting customer purchasing behavior, inventories, and revenue visibility. Management expects the pressure to persist, creating a structural regional headwind that can weigh on growth, mix, and margins until policy expectations and procurement patterns stabilize.
QuidelOrtho News
QL1A FAQ
What was QuidelOrtho’s price range in the past 12 months?
Currently, no data Available
What is QuidelOrtho’s market cap?
QuidelOrtho’s market cap is CHF613.30M.
When is QuidelOrtho’s upcoming earnings report date?
QuidelOrtho’s upcoming earnings report date is Nov 04, 2026 which is in 31 days.
How were QuidelOrtho’s earnings last quarter?
QuidelOrtho released its earnings results on Aug 06, 2026. The company reported CHF0.108 earnings per share for the quarter, beating the consensus estimate of -CHF0.041 by CHF0.149.
Is QuidelOrtho overvalued?
According to Wall Street analysts QuidelOrtho’s price is currently Undervalued.
Does QuidelOrtho pay dividends?
QuidelOrtho does not currently pay dividends.
What is QuidelOrtho’s EPS estimate?
QuidelOrtho’s EPS estimate is 0.17.
How many shares outstanding does QuidelOrtho have?
Currently, no data Available
What happened to QuidelOrtho’s price movement after its last earnings report?
QuidelOrtho reported an EPS of CHF0.108 in its last earnings report, beating expectations of -CHF0.041. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of QuidelOrtho?
Currently, no hedge funds are holding shares in CH:QL1A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
QuidelOrtho Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF12.47 (― Upside)
CHF12.47 (― Upside)
Blogger Sentiment
Neutral
CH:QL1A Sentiment 60%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
QuidelOrtho
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
QL1A Company Deck
QL1A Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed picture: solid underlying operational performance outside China (mid-single-digit growth ex-China, strong regional results, 21% YoY adjusted EBITDA growth, and margin expansion) and tangible progress on the Lex/Neulixa commercialization. Offsetting these positives were significant near-term headwinds — a 23% revenue decline in China driven by IVD pricing uncertainty, a softer respiratory season, negative operating and free cash flow in the quarter, withdrawal of free-cash-flow guidance, and elevated leverage (4.3x). Management emphasized disciplined cost actions, cash-conversion priorities, and mitigation plans, but the combination of China uncertainty and weak respiratory demand creates meaningful short-term risk even as core franchises remain resilient.View all CH:QL1A earnings summaries